Zydus gets USFDA nod to market Ibrutinib capsules 70mg
Zydus Cadila announced on Thursday that USFDA has approved it to market Ibrutinib Capsules, 70 mg and 140 mg.
According to the USFDA letter, Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib capsules, 70 mg. for these capsules, the company will have 180 days of shared generic drug exclusivity. The 70 mg capsules have a brand sales of USD 32.5 mn, while 140 mg has a brand sales of USD 745.9 mn. Zydus is the first company to receive approval for generic Ibrutinib 70 mg capsules.
Recent Posts
India Reports Highest Tuberculosis Cases in 2024 Amid Progress in TB Control
India has recorded its highest-ever number of tuberculosis (TB) cases in 2024, with 26.07 lakh…
Elon Musk’s 120-Hour Workweek: The Dark Reality
Elon Musk is known for his relentless work ethic and high expectations from his teams.…
Patanjali’s Renogrit: A Breakthrough in Kidney Protection During Cancer Treatment
In 2024, a significant advancement in nephroprotection emerged from Patanjali Research Institute with the development…
Sunita Williams & Butch Wilmore’s 45-Day Rehab After Space Mission
NASA astronauts Sunita Williams and Barry "Butch" Wilmore have returned to Earth after an extended…
Bacterial Meningitis: The Silent Threat You Can’t Ignore
Bacterial meningitis is a life-threatening infection that leads to inflammation of the meninges, the protective…
Rare Human Coronavirus HKU1 Detected in Kolkata
A 45-year-old woman from Kolkata has been diagnosed with human coronavirus HKU1 (HCoV-HKU1), a rare…